Publicaciones en las que colabora con Oreste Gualillo (21)

2023

  1. The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats

    Biomedicine and Pharmacotherapy, Vol. 161

2022

  1. Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases

    Journal of Personalized Medicine, Vol. 12, Núm. 7

  2. Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  3. The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

    Frontiers in Pharmacology, Vol. 13

2021

  1. Relaxin has beneficial effects on liver lipidome and metabolic enzymes

    FASEB Journal, Vol. 35, Núm. 7

2020

  1. Adipokines and inflammation: Focus on cardiovascular diseases

    International Journal of Molecular Sciences, Vol. 21, Núm. 20, pp. 1-34

2019

  1. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats

    Biochemical Pharmacology, Vol. 170

  2. Serelaxin (recombinant human relaxin-2) treatment affects the endogenous synthesis of long chain poly-unsaturated fatty acids and induces substantial alterations of lipidome and metabolome profiles in rat cardiac tissue

    Pharmacological Research, Vol. 144, pp. 51-65

2018

  1. Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes

    Endocrine, Vol. 60, Núm. 1, pp. 103-111

2016

  1. Endolysosomal two-pore channels regulate autophagy in cardiomyocytes

    Journal of Physiology, Vol. 594, Núm. 11, pp. 3061-3077

2015

  1. The adipokine chemerin induces apoptosis in cardiomyocytes

    Cellular Physiology and Biochemistry, Vol. 37, Núm. 1, pp. 176-192

2013

  1. Nesfatin-1 in human and murine cardiomyocytes: Synthesis, secretion, and mobilization of GLUT-4

    Endocrinology, Vol. 154, Núm. 12, pp. 4757-4767

2011

  1. Aliskiren affects fatty-acid uptake and lipid-related genes in rodent and human cardiomyocytes

    Biochemical Pharmacology, Vol. 82, Núm. 5, pp. 491-504

2010

  1. Des-acyl ghrelin has specific binding sites and different metabolic effects from ghrelin in cardiomyocytes

    Endocrinology, Vol. 151, Núm. 7, pp. 3286-3298

2007

  1. Lack of effect of the ghrelin gene-derived peptide obestatin on cardiomyocyte viability and metabolism

    Journal of Endocrinological Investigation, Vol. 30, Núm. 6, pp. 470-476

  2. The Emerging Role of Adipokines as Mediators of Cardiovascular Function: Physiologic and Clinical Perspectives

    Trends in Cardiovascular Medicine, Vol. 17, Núm. 8, pp. 275-283

2006

  1. Ghrelin In The Local Regulation Of Endocrine Glands

    Handbook of Biologically Active Peptides (Elsevier Inc.), pp. 869-875

2005

  1. Adiponectin is synthesized and secreted by human and murine cardiomyocytes

    FEBS Letters, Vol. 579, Núm. 23, pp. 5163-5169

  2. Ghrelin, the Same Peptide for Different Functions: Player or Bystander?

    Vitamins and Hormones, Vol. 71, pp. 405-432

2004

  1. GH prevents apostosis in cardiomyocytes cultured in vitro through a calcineurin-dependent mechanism

    Journal of Endocrinology, Vol. 180, Núm. 2, pp. 325-335